Omzyta Powder And Solvent For Suspension For Injection 0,5 mL Powder and Solvent for Suspension for Injection
PDF Leaflet Revision Date: 26 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Vaccination against measles, mumps, and rubella in individuals 12 months and older.
Dosage (summary)
0.5 mL intramuscularly or subcutaneously; revaccination at 4-6 years.
Special Populations
- Immunocompromised individuals
- Infants < 12 months
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid pregnancy for 1 month post-vaccination.
Key Drug Interactions
- Concurrent immune globulin may interfere with immune response
- Avoid other live vaccines within 1 month
Contraindications
- Hypersensitivity to vaccine components
- Pregnancy
- Anaphylactic reactions to neomycin
- Active febrile infections
Common side effects
- Fever
- Injection site reactions
- Rash
Counselling Points
- Inform women of childbearing age about pregnancy precautions
- Advise on potential mild side effects
- Ensure sterile technique during administration
Serious warnings
- Risk of anaphylaxis
- Monitor for fever-related stress in at-risk individuals
Important Disclaimer
The Omzyta Powder And Solvent For Suspension For Injection 0,5 mL Powder and Solvent for Suspension for Injection professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
